Publications by authors named "Steve Wenglowsky"

Claim this Profile
A
A novel DNA repair protein, N-Myc downstream regulated gene 1 (NDRG1), links stromal tumour microenvironment to chemoresistance.
Nina Kozlova, Kayla A Cruz, Hanna M Doh, Antoine A Ruzette, Nicholas A Willis, Steve Wenglowsky

bioRxiv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly potent and selective 3-N-methylquinazoline-4(3H)-one based inhibitors of B-Raf(V600E) kinase.
Steve Wenglowsky, Li Ren, Jonas Grina, Joshua D Hansen, Ellen R Laird

Bioorg Med Chem Lett· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of danoprevir (ITMN-191/R7227), a highly selective and potent inhibitor of hepatitis C virus (HCV) NS3/4A protease.
Yutong Jiang, Steven W Andrews, Kevin R Condroski, Brad Buckman, Vlad Serebryany, Steve Wenglowsky

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase.
Bradley J Newhouse, Steve Wenglowsky, Jonas Grina, Ellen R Laird, Walter C Voegtli

Bioorg Med Chem Lett· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Systemic in vitro and in vivo evaluation for determining the feasibility of making an amorphous solid dispersion of a B-Raf (rapidly accelerated fibrosarcoma) inhibitor.
Yong Cui, Po-Chang Chiang, Edna F Choo, Jason Boggs, Joachim Rudolph, Steve Wenglowsky

Int J Pharm· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolo[3,4-b]pyridine kinase inhibitors: a patent review (2008--present).
Steve Wenglowsky

Expert Opin Ther Pat· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Steve Wenglowsky, David Moreno, Ellen R Laird, Susan L Gloor, Li Ren

Bioorg Med Chem Lett· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase.
Li Ren, Kateri A Ahrendt, Jonas Grina, Ellen R Laird, Alex J Buckmelter, Steve Wenglowsky

Bioorg Med Chem Lett· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.
Simon Mathieu, Stefan N Gradl, Li Ren, Zhaoyang Wen, Ignacio Aliagas, Steve Wenglowsky

J Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing.
Steve Wenglowsky, David Moreno, Joachim Rudolph, Yingqing Ran, Kateri A Ahrendt

Bioorg Med Chem Lett· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical assessment of novel BRAF inhibitors: integrating pharmacokinetic-pharmacodynamic modelling in the drug discovery process.
Edna F Choo, Bruno Alicke, Jason Boggs, Vikki Dinkel, Stephen Gould, Steve Wenglowsky

Xenobiotica· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyridine inhibitors of B-RafV600E. Part 2: structure-activity relationships.
Steve Wenglowsky, Kateri A Ahrendt, Alex J Buckmelter, Bainian Feng, Susan L Gloor

Bioorg Med Chem Lett· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrazolopyridine Inhibitors of B-Raf(V600E). Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.
Steve Wenglowsky, Li Ren, Kateri A Ahrendt, Ellen R Laird, Ignacio Aliagas

ACS Med Chem Lett· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Alex J Buckmelter, Li Ren, Ellen R Laird, Bryson Rast, Greg Miknis, Steve Wenglowsky

Bioorg Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-oxime inhibitors of B-Raf(V600E) kinase.
Li Ren, Steve Wenglowsky, Greg Miknis, Bryson Rast, Alex J Buckmelter

Bioorg Med Chem Lett· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomimetic macrocycle-forming Diels-Alder reaction of an iminium dienophile: synthetic studies directed toward gymnodimine.
Jeffrey W Johannes, Steve Wenglowsky, Yoshito Kishi

Org Lett· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis